Nanostics has secured funding from Genome Canada and Genome Alberta to expedite the ClarityDX Prostate test integration into the standard of care for prostate cancer screening throughout the country.
The funding, secured through the Canadian Biotechnology Innovation and Commercialization Initiative (CBIC), is set to accelerate the adoption of the test, starting in Alberta and eventually nationwide.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This initiative is driven by partnerships in academia, clinical practice, and economics, under the guidance of the University of Alberta Translational Oncology Bird Dogs Chair Dr John Lewis, as well as collaborations with Partnerships and Innovation at Acute Care Alberta and Nanostics.
The laboratory-developed test employs machine learning to assess the risk of aggressive prostate cancer.
It combines blood-based biomarkers and clinical data to predict the likelihood of significant prostate cancer and is available as a patient-pay test at present.
The project’s main goal is to compile a comprehensive evidence package to show the clinical efficacy and economic benefits of the test.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThis is crucial for the reimbursement and public accessibility and will include outcomes from various studies, including health impact feasibility, clinical utility, and health system integration.
Dr Lewis said: “We are very grateful for Genome Canada’s support of this project.
“This unique opportunity to collaborate directly with Acute Care Alberta will accelerate adoption of ClarityDX Prostate, and more importantly, help improve the outcomes of men in their journey of screening and diagnosis for prostate cancer.”
ClarityDX Prostate aids male subjects and their healthcare providers to make informed decisions regarding the need for a biopsy after a high prostate-specific antigen (PSA) test or an abnormal digital rectal exam (DRE).
Its availability spans several Canadian provinces, including Alberta, Quebec, Ontario, British Columbia, and Saskatchewan.
Last year, the company collaborated with OncoHelix to extend the reach of ClarityDX Prostate to the Middle East, providing the blood test to healthcare providers and patients in the region.
